IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 37 filers reported holding IMPEL NEUROPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,083 | -66.1% | 14,145 | 0.0% | 0.00% | -100.0% |
Q2 2023 | $17,965 | -9.3% | 14,145 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $19,803 | -62.7% | 14,145 | 0.0% | 0.00% | -66.7% |
Q4 2022 | $53,044 | -23.1% | 14,145 | 0.0% | 0.00% | -25.0% |
Q3 2022 | $69,000 | -47.7% | 14,145 | 0.0% | 0.00% | -50.0% |
Q2 2022 | $132,000 | +45.1% | 14,145 | -0.5% | 0.01% | +100.0% |
Q1 2022 | $91,000 | -25.4% | 14,215 | +0.5% | 0.00% | -33.3% |
Q4 2021 | $122,000 | – | 14,145 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NVP Associates, LLC | 3,077,198 | $11,539,493 | 11.26% |
Vivo Capital, LLC | 2,884,789 | $43,272 | 4.98% |
venBio Partners LLC | 2,759,791 | $10,349,216 | 3.21% |
5AM Venture Management, LLC | 2,884,791 | $10,817,966 | 2.91% |
LASRY MARC | 408,329 | $1,531,234 | 2.38% |
DCF Advisers, LLC | 325,825 | $1,221,844 | 0.83% |
Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $15,509,891 | 0.52% |
EPIQ PARTNERS, LLC | 18,646 | $69,923 | 0.05% |
J. Goldman & Co LP | 200,219 | $750,821 | 0.04% |
MCDONALD PARTNERS LLC | 11,700 | $43,875 | 0.02% |